IP Library Granted Patent US 8,263,757
Granted Patent B2
US 8,263,757 · App. 13/149,408 · Granted Sep 11, 2012

Promiscuous HER-2/Neu CD4 T cell epitopes

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,263,757
App. No.
13/149,408
Granted
Sep 11, 2012
Kind
B2
Abstract

The present invention relates to the discovery of novel T cell epitopes of the human HER-2/Neu protein that is promiscuous for at least 25 different HLA-DR alleles. The invention also relates to compositions that contain one of the novel epitopes or a fusion peptide of such a epitope and a heterologous polypeptide. Further disclosed herein is the use of the epitopes or their fusion peptides, and compositions containing the epitopes or their fusion peptides.

Claims (12)

1. An isolated nucleic acid consisting of a polynucleotide sequence encoding the amino acid sequence of SEQ ID NOs: 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 31.

2. An isolated nucleic acid comprising a polynucleotide sequence encoding a fusion peptide consisting of the amino acid sequence of SEQ ID NOs: 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 31 and a heterologous polypeptide.

3. The nucleic acid of claim 1 or 2 , wherein the polynucleotide sequence encodes the amino acid sequence of SEQ ID NO:2.

4. The nucleic acid of claim 2 , wherein the heterologous polypeptide is a granulocyte-macrophage colony-stimulating factor (GM-CSF).

5. An expression cassette comprising the nucleic acid of claim 1 or 2 .

6. The expression cassette of claim 5 , which is a recombinant viral vector.

7. The expression cassette of claim 5 , which directs the expression of the nucleic acid of claim 1 or 2 .

8. A host cell comprising the expression cassette of claim 5 .

9. A host cell comprising the expression cassette of claim 6 .

10. The isolated nucleic acid of claim 1 , wherein the polynucleotide sequence encodes the amino acid sequence of SEQ ID NOs: 20, 21, 22, or 23.

11. The isolated nucleic acid of claim 1 , wherein the polynucleotide sequence encodes the amino acid sequence of SEQ ID NOs: 24, 25, or 26.

12. The isolated nucleic acid of claim 1 , wherein the polynucleotide sequence encodes the amino acid sequence of SEQ ID NOs: 27, 28, 29, or 31.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED AT REEL: 042389 FRAME: 505. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Feb 14, 2018
From: DENDREON PHARMACEUTICALS, INC.
To: DENDREON PHARMACEUTICALS LLC
Reel/Frame 046088/0882 →
RELEASE OF SECURITY INTEREST Recorded Jul 5, 2017
From: BARCLAYS BANK PLC
To: DENDREON PHARMACEUTICALS LLC
Reel/Frame 043089/0288 →
CHANGE OF NAME Recorded May 3, 2017
From: DENDREON PHARMACEUTICALS, INC.
To: DENDREON PHARMACEUTICALS LLC
Reel/Frame 042389/0505 →